A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013). 2023 American Society of Clinical Oncology

Rupesh Kotecha

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013). 2023 American Society of Clinical Oncology

Rupesh Kotecha

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Jun 2 2023

Cite this

@conference{4432a1e0425b4201aa5318f1f996cab3,

title = "A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT\# 04511013). 2023 American Society of Clinical Oncology",

author = "Rupesh Kotecha",

year = "2023",

month = jun,

day = "2",

language = "American English",

}

TY - CONF

T1 - A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013). 2023 American Society of Clinical Oncology

AU - Kotecha, Rupesh

PY - 2023/6/2

Y1 - 2023/6/2

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4877

M3 - Presentation

ER -

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT# 04511013). 2023 American Society of Clinical Oncology

Other files and links

Cite this